+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 74Years
All Genders
ID07746544

Evaluation of Oral Secutrelvir Compared to Placebo for Treatment of COVID-19 Symptoms in Nonhospitalized Participants

Led by Shionogi · Updated on 2026-09-02

1200

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of secutrelvir compared to a placebo in people aged 12 to 74 who have COVID-19 but are not hospitalized. The study focuses on how quickly clinical symptoms resolve when starting treatment within 48 hours of symptom onset. This Phase 3 study aims to understand the treatments safety and effectiveness in relieving COVID-19 symptoms. Participants will be randomly assigned to receive either secutrelvir or a placebo, both given as oral tablets. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment begins promptly within 48 hours of symptom start, and participants are monitored throughout the study period. During the study, participants will be regularly assessed for the resolution and alleviation of 14 specific COVID-19 symptoms, fever reduction, and viral levels in the body. Safety is monitored by tracking any treatment-emergent adverse events. The primary outcome measure is the time to first resolution of symptoms within 21 days. The study lasts until primary completion around July 2027 with follow-up assessments continuing through 28 days after treatment begins.

CONDITIONS

Brief Title

Study of Secutrelvir in Participants With COVID-19

Research Team

S

Shionogi Clinical Trials Administrator Clinical Support Help Line

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here